278 related articles for article (PubMed ID: 32003806)
21. 18F-fluorodeoxyglucose positron emission tomographic scan in solid-type p-stage-I pulmonary adenocarcinomas: what can produce false-negative results?
Lococo F; Galeone C; Formisano D; Bellafiore S; Filice A; Annunziata T; Cesario A; Rapicetta C; Fioroni F; Ricchetti T; Paci M
Eur J Cardiothorac Surg; 2017 Apr; 51(4):667-673. PubMed ID: 28043987
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
Tsutani Y; Takuwa T; Miyata Y; Fukuoka K; Hasegawa S; Nakano T; Okada M
Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
[TBL] [Abstract][Full Text] [Related]
23. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
24. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
Gerbaudo VH; Mamede M; Trotman-Dickenson B; Hatabu H; Sugarbaker DJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):810-21. PubMed ID: 21210110
[TBL] [Abstract][Full Text] [Related]
25. Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.
Fodor A; Broggi S; Incerti E; Dell'Oca I; Fiorino C; Samanes Gajate AM; Pasetti M; Cattaneo MG; Passoni P; Gianolli L; Calandrino R; Picchio M; Di Muzio N
Clin Lung Cancer; 2019 Jan; 20(1):e29-e38. PubMed ID: 30253920
[TBL] [Abstract][Full Text] [Related]
26. The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
Klabatsa A; Chicklore S; Barrington SF; Goh V; Lang-Lazdunski L; Cook GJ
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):276-82. PubMed ID: 24057459
[TBL] [Abstract][Full Text] [Related]
27. Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma.
Frauenfelder T; Kestenholz P; Hunziker R; Nguyen TD; Fries M; Veit-Haibach P; Husmann L; Stahel R; Weder W; Opitz I
J Comput Assist Tomogr; 2015; 39(2):160-5. PubMed ID: 25354093
[TBL] [Abstract][Full Text] [Related]
28. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
Kitajima K; Doi H; Kuribayashi K
Jpn J Radiol; 2016 Aug; 34(8):537-47. PubMed ID: 27222020
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of 18F-FDG PET/CT in malignant pleural mesothelioma: a meta-analysis.
Wang Y; Xu Y; Kan Y; Wang W; Yang J
Acta Radiol; 2023 Feb; 64(2):552-562. PubMed ID: 35315714
[TBL] [Abstract][Full Text] [Related]
30. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
31. Pleural tuberculosis mimicking malignant pleural mesothelioma by
Ai L; Wang W; Li Y
Med Clin (Barc); 2023 Nov; 161(9):415. PubMed ID: 37263842
[No Abstract] [Full Text] [Related]
32. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.
Krüger S; Pauls S; Mottaghy FM; Buck AK; Schelzig H; Hombach V; Reske SN
Nuklearmedizin; 2007; 46(6):239-43. PubMed ID: 18084678
[TBL] [Abstract][Full Text] [Related]
33. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
Basu S; Saboury B; Torigian DA; Alavi A
Mol Imaging Biol; 2011 Oct; 13(5):801-11. PubMed ID: 21136185
[TBL] [Abstract][Full Text] [Related]
34. The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma.
Ozmen O; Koyuncu A; Koksal D; Tatci E; Alagoz E; Demirag F; Gokcek A; Arslan N
Nucl Med Commun; 2016 Jan; 37(1):43-9. PubMed ID: 26440572
[TBL] [Abstract][Full Text] [Related]
35. Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
Huang YC; Tu DG; Wu JD; Lee MY
Spine (Phila Pa 1976); 2009 Oct; 34(21):E780-3. PubMed ID: 19934799
[TBL] [Abstract][Full Text] [Related]
36. Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
Schaarschmidt BM; Sawicki LM; Gomez B; Grueneisen J; Hoiczyk M; Heusch P; Buchbender C
Clin Imaging; 2016; 40(5):956-60. PubMed ID: 27232931
[TBL] [Abstract][Full Text] [Related]
37. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
Nanni C; Castellucci P; Farsad M; Pinto C; Moretti A; Pettinato C; Marengo M; Boschi S; Franchi R; Martoni A; Monetti N; Fanti S
Cancer Biother Radiopharm; 2004 Apr; 19(2):149-54. PubMed ID: 15186594
[TBL] [Abstract][Full Text] [Related]
38. Histology of the pleural rind at [
Soltermann A; Opitz I; Burger IA
Pathol Res Pract; 2021 Dec; 228():153660. PubMed ID: 34749212
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
Schneider DB; Clary-Macy C; Challa S; Sasse KC; Merrick SH; Hawkins R; Caputo G; Jablons D
J Thorac Cardiovasc Surg; 2000 Jul; 120(1):128-33. PubMed ID: 10884665
[TBL] [Abstract][Full Text] [Related]
40. Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
Abakay A; Komek H; Abakay O; Palanci Y; Ekici F; Tekbas G; Tanrikulu AC
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1233-41. PubMed ID: 23690193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
